| human | Q5 |
| P496 | ORCID iD | 0000-0002-9872-6242 |
| P108 | employer | University of California, San Diego | Q622664 |
| P734 | family name | Cohen | Q1158586 |
| Cohen | Q1158586 | ||
| Cohen | Q1158586 | ||
| P735 | given name | Ezra | Q17642702 |
| Ezra | Q17642702 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q45825472 | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016. |
| Q47125349 | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016 |
| Q36217637 | A Mechanism-Based Approach to the Management of Osteoarthritis Pain |
| Q35980854 | A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis |
| Q64079625 | A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy |
| Q80726082 | A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck |
| Q37351453 | A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle |
| Q30434796 | A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers |
| Q89282213 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors |
| Q41173029 | A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer |
| Q31123048 | A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia |
| Q46991010 | A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer |
| Q81388286 | A phase II study of ABT-751 in patients with advanced non-small cell lung cancer |
| Q35743883 | A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. |
| Q53619106 | A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. |
| Q91695844 | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
| Q42707218 | A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours |
| Q48068818 | A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases |
| Q81408649 | A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores |
| Q55265358 | Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). |
| Q36822111 | Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer |
| Q47697133 | Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association |
| Q35290247 | Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies |
| Q42863527 | Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer |
| Q92871876 | Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial |
| Q35822882 | Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo |
| Q27853153 | Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial |
| Q34896542 | Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c |
| Q92716157 | Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial |
| Q37850758 | Airway management before chemoradiation for advanced head and neck cancer |
| Q26752802 | American Cancer Society Head and Neck Cancer Survivorship Care Guideline |
| Q35911903 | An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. |
| Q38432573 | An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck |
| Q45152949 | Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment |
| Q37329842 | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize |
| Q36640608 | Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer |
| Q36877022 | Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study |
| Q90468882 | B-cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade |
| Q38056076 | Cabozantinib for the treatment of advanced medullary thyroid cancer |
| Q34185084 | Cabozantinib in progressive medullary thyroid cancer |
| Q44170385 | Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study |
| Q46308299 | Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer |
| Q43463771 | Chemoradiation for patients with advanced oral cavity cancer |
| Q50995911 | Chemoradiation for patients with large-volume laryngeal cancers. |
| Q37359022 | Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology |
| Q91287379 | Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology |
| Q102388956 | Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer |
| Q46017774 | Considering the survivorship care needs of head and neck cancer survivors. |
| Q39489743 | Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer |
| Q54443871 | Corrigendum: PI3Kγ is a molecular switch that controls immune suppression. |
| Q92582957 | Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States |
| Q38583290 | Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| Q35206363 | DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer |
| Q88505550 | Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience |
| Q46041411 | Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents |
| Q33525226 | Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients |
| Q38090739 | Diarrhea associated with afatinib: an oral ErbB family blocker |
| Q84005593 | Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors |
| Q83215218 | Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244 |
| Q97677273 | Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children |
| Q87668354 | Editorial for special issue on nasopharynx cancer |
| Q89182516 | Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial |
| Q37128767 | Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis |
| Q37430131 | Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy |
| Q46643584 | Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model |
| Q36278199 | Epidermal growth factor receptor directed therapy in head and neck cancer |
| Q33990915 | Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer |
| Q33406802 | Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study |
| Q36631786 | Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. |
| Q36906428 | Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients |
| Q49668969 | Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. |
| Q61851260 | Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas |
| Q37740827 | Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas |
| Q36377940 | Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab |
| Q42775070 | Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer |
| Q46036998 | Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. |
| Q37265167 | Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib |
| Q53340009 | Forthcoming receptor tyrosine kinase inhibitors. |
| Q37204893 | Free-flap reconstruction in the doubly irradiated patient population |
| Q41496425 | Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. |
| Q34820601 | Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers |
| Q92057594 | HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer |
| Q35601686 | High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial |
| Q81260544 | Hot topics issue: immunotherapy of cancer |
| Q91983062 | Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics |
| Q90994251 | Immunotherapeutic Approaches to the Management of Head and Neck Cancer |
| Q45998119 | Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. |
| Q36914455 | Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy |
| Q35684091 | Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer |
| Q35920853 | Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma |
| Q41607812 | Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes |
| Q35008028 | Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas |
| Q44552813 | Introduction: head and neck cancer |
| Q37161155 | Iodine-refractory thyroid carcinoma. |
| Q38964554 | Kawasaki Disease at 50 Years |
| Q38543203 | Laryngeal sarcoidosis: presentation and management in the pediatric population |
| Q38612894 | Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma |
| Q93349585 | Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens |
| Q30383394 | Measuring the development of integrative care communication patterns and cross-disciplinary knowledge at a university clinic: a baseline cross-sectional study. |
| Q38366098 | Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). |
| Q42259460 | MicroRNA-regulated feed forward loop network |
| Q36941427 | Modifiable risk behaviors in patients with head and neck cancer |
| Q36868012 | Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition |
| Q46633214 | Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine |
| Q34098286 | Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss |
| Q38924337 | Multidisciplinary Care of Laryngeal Cancer |
| Q38085840 | Multidisciplinary care of the patient with head and neck cancer |
| Q41127315 | New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors |
| Q37872269 | Novel molecular targeted therapies for refractory thyroid cancer |
| Q37975224 | Novel targeted therapies in head and neck cancer |
| Q35984741 | Novel therapeutic targets in squamous cell carcinoma of the head and neck |
| Q85942123 | Open Access in biomedical sciences: what the current turning point means more specifically to Oral Oncology contributors and readers |
| Q33822173 | PI3Kγ is a molecular switch that controls immune suppression |
| Q90224620 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study |
| Q48438158 | Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy |
| Q38090946 | Pharmacoeconomic issues in head and neck oncology |
| Q44982199 | Pharmacokinetics of single-agent axitinib across multiple solid tumor types. |
| Q35542196 | Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients |
| Q46674514 | Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer |
| Q79757577 | Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer |
| Q57272626 | Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands |
| Q37505185 | Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements |
| Q42644659 | Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck |
| Q33385634 | Phase II study of sunitinib malate in head and neck squamous cell carcinoma |
| Q34533587 | Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck |
| Q34563033 | Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q34430205 | Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer |
| Q46086817 | Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. |
| Q82567321 | Planned post-chemoradiation neck dissection: significance of radiation dose |
| Q55174606 | Positive Surgical Margins in the 10 Most Common Solid Cancers. |
| Q90616314 | Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability |
| Q46215317 | Predictors of competing mortality in advanced head and neck cancer |
| Q84357377 | Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation |
| Q59350670 | Proceedings of the 2016 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting : Toronto, Canada. 14-17 April 2016 |
| Q89022300 | Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer |
| Q40266943 | Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase |
| Q46066022 | Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy |
| Q44405597 | Race and competing mortality in advanced head and neck cancer |
| Q58606460 | Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response |
| Q38827912 | Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline |
| Q89128628 | Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma |
| Q42775567 | Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma |
| Q33839177 | Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy |
| Q92034178 | Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors |
| Q86701395 | Reply to s. Chakraborty et al |
| Q46813416 | Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. |
| Q46599914 | Reviews on Recent Clinical Trials. Tyrosine kinases. |
| Q38401920 | Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. |
| Q39243029 | Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis |
| Q36500969 | Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q92263399 | SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q96031183 | Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study |
| Q43851409 | Searching for a standard |
| Q90456587 | Selection of Head and Neck Cancer Patients for Intensive Therapy |
| Q36368035 | Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide |
| Q46015106 | Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. |
| Q34145659 | Single sample expression-anchored mechanisms predict survival in head and neck cancer |
| Q39931776 | Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line |
| Q45170619 | Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease |
| Q34563951 | Stimuli-responsive magnetic nanomicelles as multifunctional heat and cargo delivery vehicles |
| Q37232007 | Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy |
| Q57286702 | Summary of the third World Congress on Thyroid Cancer |
| Q35551059 | Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy |
| Q91717183 | Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4 |
| Q97566897 | Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study |
| Q60369025 | Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial |
| Q81432875 | Targeting angiogenesis in head and neck cancer |
| Q38297381 | Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck |
| Q46035468 | The ACR appropriateness criteria® for thyroid carcinoma: searching for consensus in a rapidly evolving area. |
| Q101120479 | The Changing Landscape of Therapeutic Cancer Vaccines - Novel Platforms and Neoantigen Identification |
| Q30494514 | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma |
| Q91895909 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) |
| Q35676430 | The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients |
| Q35760433 | The expanding role of systemic therapy in head and neck cancer |
| Q43557313 | The future of induction chemotherapy for head and neck squamous cell carcinoma |
| Q39775882 | The next phase of chemoprevention research |
| Q38417485 | The rise of HPV-positive oropharyngeal cancers in the United States |
| Q38017859 | The role of chemotherapy in locally advanced head and neck squamous cell carcinoma |
| Q81782171 | Thrombolytic therapy for acute stroke in late pregnancy with intra-arterial recombinant tissue plasminogen activator |
| Q45017077 | Thyroid special issue |
| Q96584096 | Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer |
| Q38493791 | Towards a personalized treatment of head and neck cancer |
| Q48075919 | Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments |
| Q37017674 | Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors |
| Q34795914 | Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies |
| Q27853396 | Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial |
| Q42981913 | [18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality |
| Q36430449 | mTOR inhibitors. |
| Q46803176 | mTOR: the mammalian target of replication |
| Q90688849 | p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply |
| Q28540464 | p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors |
Search more.